Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model

Fig. 1

AVX235 effects downstream metabolites of cPLA2α. a After 2 days of AVX235 treatment, samples from treated mice (grey triangles) had significantly lower PGE2 levels compared to controls (black dots). PGE2 levels are normalized to RNA levels. Each symbol indicates the mean of 2–7 replicate measurements of the same tumor sample and/or different samples from the same tumor. Horizontal lines indicate group medians. * p < 0.05, two-tailed Mann–Whitney U test. b-c PLS-DA of HR MAS MR spectra from 2-day samples. b Scores plot showing separation of control and treated samples (n = 6 per group). c Loadings plot of the first two latent variables (LV1 and LV2) in the PLS-DA model. The VIP scores show that the most influential metabolites are PCho at 3.23 ppm and GPC at 3.24 ppm

Back to article page